dxy logo
首页丁香园病例库全部版块
搜索
登录

【drug-news】世界10大重磅药,品种,厂家,销量和适应症

最后编辑于 2022-10-09 · IP 浙江浙江
8364 浏览
这个帖子发布于 14 年零 233 天前,其中的信息可能已发生改变或有所发展。
世界10大重磅药,品种,厂家,销量和适应症

Lipitor
Maker: Pfizer
Sales Rank: 1
Technology: Chiral chemistry
2009 Sales: $12.5 billion

Indications: Hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) to reduce total cholesterol

Plavix
Maker: Bristol-Myers Squibb and Sanofi-Aventis
Sales Rank: 2
Technology: Small molecule
2009 Sales: $9.5 billion

Indications: Heart attack and stroke prevention

Advair
Maker: GlaxoSmithKline
Sales Rank: 3
Technology: Small Molecule
2009 Sales: $7.7 billion

Indications: Asthma and COPD

Enbrel
Maker: Amgen
Sales Rank: 4
Technology: Recombinant product
2009 Sales: $6.2 billion

Indications: Rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, chronic plaque psoriasis

Diovan
Maker: Novartis
Sales Rank: 5
Technology: Small Molecule
2009 Sales: $6.0 billion

Indications: Hypertension and congestive heart failure

Remicade
Maker: Johnson & Johnson
Sales Rank: 6
Technology: Monoclonal antibody
2009 Sales: $5.9 billion

Indications: Plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults, pediatric Crohn's disease, ulcerative colitis, and ankylosing spondylitis

Avastin
Maker: Roche/Genentech
Sales Rank: 7
Technology: Monoclonal antibody
2009 Sales: $5.7 billion

Indications: Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Glioblastoma, Metastatic Kidney Cancer

Rituxan
Maker: Roche/Genentech
Sales Rank: 8
Technology: Monoclonal antibody
2009 Sales: $5.6 billion

Indications: Non-Hodgkin's lymphoma, Chronic Lymhocytic leukemia, Rheumatoid arthritis

Humira
Maker: Abbott Pharmaceuticals
Sales Rank: 9
Technology: Monoclonal antibody
2009 Sales: $5.5 billion

Indications: Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis (AS) in adults, Crohn's disease, Plaque psoriasis

Seroquel
Maker: AstraZeneca
Sales Rank: 10
Technology: Small molecule
2009 Sales: $5.1 billion

Indications: Major depressive disorder, Acute depressive episodes in bipolar disorder, Acute manic or mixed episodes in bipolar disorder alone or with lithium or divalproex; Long-term treatment of bipolar disorder with lithium or divalproex, and Schizophrenia

From Fiercebiotech top blockbuster Rx

















































































38 25 2

全部讨论(0)

默认最新
avatar
38
分享帖子
share-weibo分享到微博
share-weibo分享到微信
认证
返回顶部